Since tamoxifen-based endocrine therapy is the mainstay of adjuvant therapy for ER+ breast cancer, a major concern with endocrine therapy is the development of acquired resistance in approximately 40% of patients who receive tamoxifen.86 This evidence concerns the gene ESR1 and breast carcinoma.